

### CERTIFICATE OF ANALYSIS

**Order Type:** Medical Cannabis  
**Order ID:** OR2019-1367

**Customer ID:** 32  
**Customer Name:** CBD Plus USA

**Harvest/Extract Lot:** None  
**Harvest/Extract Batch:** None

**Cultivar (Strain):** Bath Bomb Love  
 Spell CBD

**Lab ID:** SA2019-4777

**Sample Matrix:** Other

**Sample Date:** 05/03/2019

**Date Received:** 05/03/2019

**Date Completed:** 05/03/2019

**Remarks:**

### CANNABINOID (POTENCY) PROFILE

**Analysis Date/Time:** 05/03/2019 1408

**Method:** HPLC/DAD (Internal Method-001)


**Moisture Content (%):** -

**Analyst:** OL

**Instrument:** Agilent 1100

**Water Activity (aw):** -

Cannabinoid	Result (%)	Result (mg/g)	Reporting Limit (mg/g)	Per Unit (mg)
CBD	0.0869	0.869	0.0246	96
CBDa	-	-	0.0246	-
CBDv	-	-	0.0246	-
Δ9-THC	-	-	0.0246	-
Δ8-THC	-	-	0.0246	-
THCa	-	-	0.0246	-
THCv	-	-	0.0246	-
CBC	-	-	0.0246	-
CBG	-	-	0.0246	-
CBGa	-	-	0.0246	-
CBN	-	-	0.0246	-



**TOTAL** 0.0869 0.869 96

**UNIT MASS (g):** 110


**TOTAL THC** - - -

"-" Not detected above RL.

**TOTAL CBD** 0.0869 0.869 96

### Cannabinoid Distribution

(% of Total Cannabinoids)



Deviations from standard operating procedure: None

Recoveries for all analyte standards: 90-110%

Replicate Uncertainties: <5% RSD, <20% RPD

Sample/Reagent Blanks: <RL for all analytes

Values for plant matter are adjusted for moisture content.

Total THC = (THCa x 0.877) + Δ9-THC

Total CBD = (CBDa x 0.877) + CBD

Percentage results are reported by mass.

mg/g results are reported as mass component per mass material.

**Abbreviations:** UV - Ultraviolet, HPLC - High Pressure Liquid Chromatography, RL - Reporting Limit, RPD - Relative Percent Difference, RSD - Relative Standard Deviation

This information is provided as a service and makes no claims of efficacy and/or safety of this product. Results are applicable only for the sample(s) analyzed and for the specific analysis conducted. This report is for informational purposes only and should not be used to diagnose, treat, or prevent any medical-related symptoms.

The statements and results herein have not been approved and/or endorsed by the FDA.

### REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full, without the written consent of Felling Analytical Services and Technology (F.A.S.T.), LLC

*Kyle W. Felling*  
 Kyle W. Felling, Ph.D.  
 Laboratory Director

[www.FASTLaboratories.com](http://www.FASTLaboratories.com)